- The Wall Street Journal•3 hours ago
European central banks are looking to corporate debt to help get the region’s economy firing on all cylinders again, but many companies are wary of investing the proceeds from those purchases.
- Investor's Business Daily•17 hours ago
The FDA could approve a breakthrough adult eczema treatment from Regeneron and Sanofi as soon as March.
- Zacks•18 hours ago
Regeneron (REGN) and partner Sanofi's atopic dermatitis treatment, dupilumab, is under priority review in the U.S. A response should be out by Mar 29, 2017.
NYSE - NYSE Real Time Price. Currency in USD
|Bid||37.97 x 1300|
|Ask||37.99 x 4200|
|Day's Range||37.82 - 38.14|
|52wk Range||37.41 - 51.88|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||21.25|
|Avg Vol (3m)||2,444,351|
|Dividend & Yield||1.66 (4.34%)|